Travis Murdoch, HI-Bio CEO
May 24, 2024 07:26 AM EDTUpdated 09:22 AM
R&D

HI-Bio out­lines da­ta that sparked $1.15B Bio­gen buy­out

Max Gelman

Senior Editor

Days af­ter get­ting ac­quired by Bio­gen, Hu­man Im­munol­o­gy Bio­sciences re­vealed Phase 2 da­ta that helped seal the deal.

In the tri­al, which looked at the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly be­comes the lat­est phar­ma to tap Ope­nAI for help, this time for an­tibi­ot­ic work

New can­cer biotech emerges from Stan­ford re­search, with help of No­bel lau­re­ate Car­olyn Bertozzi

Gink­go to cut at least 35% of staff in mul­ti-year re­struc­tur­ing plan

Can CRISPR be giv­en twice? Small study from In­tel­lia sug­gests it can

Ar­row­head shelves one car­diometa­bol­ic drug can­di­date, fo­cus­es on an­oth­er

Ex-Meta sci­en­tists launch Evo­lu­tion­aryScale with $142M seed round, un­veil­ing next-gen AI mod­el for pro­tein de­sign

A service from the Financial Times